Literature DB >> 19800445

Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.

Richarda M de Voer1, Fiona R M van der Klis, Carla W A M Engels, Rutger M Schepp, Jan van de Kassteele, Elisabeth A M Sanders, Ger T Rijkers, Guy A M Berbers.   

Abstract

In the Netherlands the meningococcal serogroup C conjugate (MenCC) vaccine is administered as a single dose at 14 months. We evaluated the kinetics of isotype-specific antibodies in adults (n=21) after primary immunization with MenCC or secondary immunization with MenCC or plain MenC polysaccharide vaccine. Blood samples were collected prior to immunization and at 6 additional time points, from 3 to 25 days post-immunization. Secondary immunization resulted in 5-10-fold higher IgG titers compared to the primary immunization group, 25 days post-immunization. Prior to the secondary immunization, but 5 years after the first immunization, protective bactericidal antibodies and levels of MenC-specific IgG and IgM were still present. Furthermore, IgG antibodies present before secondary immunization were of higher avidity compared to antibodies produced one month after primary immunization. In addition, secondary immunization with nonconjugated MenC polysaccharide seemed to induce a higher IgG2 response compared to MenCC immunization. The kinetics of the observed secondary immune responses were not really faster than the observed primary responses. However, the rate of increase in antibodies seemed faster than the primary responses, representing a booster response. As the course of infection by Neisseria meningitidis can be very rapid, these data support the idea that sustainment of high antibody levels induced by MenCC are important for immediate protection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19800445     DOI: 10.1016/j.vaccine.2009.09.082

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Impaired antibody response to conjugated meningococcal serogroup C vaccine in asplenic patients.

Authors:  A Meerveld-Eggink; O de Weerdt; R M de Voer; G A M Berbers; H van Velzen-Blad; B J Vlaminckx; D H Biesma; G T Rijkers
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-24       Impact factor: 3.267

2.  Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.

Authors:  Susanne P Stoof; Mariëtte B van Ravenhorst; Debbie M van Rooijen; Richarda M de Voer; Fiona R M van der Klis; Greet J Boland; Elisabeth A M Sanders; Guy A M Berbers; Peter F Teunis
Journal:  Clin Vaccine Immunol       Date:  2017-02-06

3.  Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.

Authors:  H Findlow; R Borrow; P Hardelid; E Newton; S Frankland; S Naylor; E Miller; E Kaczmarski; R C Read
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

4.  Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.

Authors:  S M Niaz Arifin; Christoph Zimmer; Caroline Trotter; Anaïs Colombini; Fati Sidikou; F Marc LaForce; Ted Cohen; Reza Yaesoubi
Journal:  Med Decis Making       Date:  2019-07-03       Impact factor: 2.583

5.  Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.

Authors:  Richarda M de Voer; Liesbeth Mollema; Rutger M Schepp; Sabine C de Greeff; Pieter G M van Gageldonk; Hester E de Melker; Elisabeth A M Sanders; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

6.  Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Rutger M Schepp; Ger T Rijkers; Elisabeth A M Sanders; Guy A M Berbers
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

7.  Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.

Authors:  Patricia Kaaijk; Arie van der Ende; Guy Berbers; Germie P J M van den Dobbelsteen; Nynke Y Rots
Journal:  BMC Infect Dis       Date:  2012-02-08       Impact factor: 3.090

8.  Meningococcal conjugate vaccines: optimizing global impact.

Authors:  Andrew Terranella; Amanda Cohn; Thomas Clark
Journal:  Infect Drug Resist       Date:  2011-09-21       Impact factor: 4.003

9.  Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine.

Authors:  Johannes Elias; Jamie Findlow; Ray Borrow; Angelika Tremmel; Matthias Frosch; Ulrich Vogel
Journal:  J Occup Med Toxicol       Date:  2013-03-04       Impact factor: 2.646

10.  Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.

Authors:  Daniel Holme; Helen Findlow; Samba O Sow; Olubukola T Idoko; Marie-Pierre Preziosi; George Carlone; Brian D Plikaytis; Ray Borrow
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.